Orgenesis Inc. offers biotechnology solutions focusing on cell and gene therapies (CGTs). More Details
Flawless balance sheet and overvalued.
Share Price & News
How has Orgenesis's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ORGS has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: ORGS exceeded the US Biotechs industry which returned 32.5% over the past year.
Return vs Market: ORGS exceeded the US Market which returned 17.8% over the past year.
Price Volatility Vs. Market
How volatile is Orgenesis's share price compared to the market and industry in the last 5 years?
Simply Wall St News
6 days ago | Simply Wall StIs Orgenesis (NASDAQ:ORGS) Weighed On By Its Debt Load?
1 month ago | Simply Wall StWhat Kind Of Shareholders Hold The Majority In Orgenesis Inc.'s (NASDAQ:ORGS) Shares?
3 months ago | Simply Wall StCan You Imagine How Orgenesis' (NASDAQ:ORGS) Shareholders Feel About The 31% Share Price Increase?
Is Orgenesis undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ORGS's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ORGS's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ORGS is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: ORGS is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ORGS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ORGS is good value based on its PB Ratio (1.2x) compared to the US Biotechs industry average (3.4x).
How is Orgenesis forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Orgenesis has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine Orgenesis's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Orgenesis performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ORGS is currently unprofitable.
Growing Profit Margin: ORGS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ORGS is unprofitable, and losses have increased over the past 5 years at a rate of 42% per year.
Accelerating Growth: Unable to compare ORGS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ORGS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.1%).
Return on Equity
High ROE: ORGS has a negative Return on Equity (-53.14%), as it is currently unprofitable.
How is Orgenesis's financial position?
Financial Position Analysis
Short Term Liabilities: ORGS's short term assets ($104.3M) exceed its short term liabilities ($19.8M).
Long Term Liabilities: ORGS's short term assets ($104.3M) exceed its long term liabilities ($11.0M).
Debt to Equity History and Analysis
Debt Level: ORGS's debt to equity ratio (12.1%) is considered satisfactory.
Reducing Debt: ORGS had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ORGS has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ORGS has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 53.6% each year.
What is Orgenesis's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ORGS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ORGS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ORGS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ORGS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ORGS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Vered Caplan (51 yo)
Ms. Vered Caplan, M.Sc., has been the President and Chief Executive Officer of Orgenesis Inc. since August 14, 2014. Ms. Caplan is the Sole Owner of PBD Ltd. Ms. Caplan has been the Chief Executive Officer ...
CEO Compensation Analysis
Compensation vs Market: Vered's total compensation ($USD1.40M) is above average for companies of similar size in the US market ($USD578.04K).
Compensation vs Earnings: Vered's compensation has increased whilst the company is unprofitable.
|Chairperson of the Board||6.83yrs||US$1.40m||no data|
|Member of Advisory Board||1yr||no data||no data|
|Independent Director||8.5yrs||US$157.00k||no data|
|Member of Advisory Board||7.5yrs||US$9.41k||no data|
|Independent Director||7.25yrs||US$181.12k||no data|
|Independent Director||8.5yrs||US$157.00k||0.29% |
|Member of Advisory Board||8.5yrs||US$67.20k||no data|
|Independent Director||0.75yr||no data||no data|
|Member of Advisory Board||0.58yr||no data||no data|
|Independent Director||3.67yrs||US$151.06k||no data|
|Member of Advisory Board||2.5yrs||no data||no data|
|Member of Advisory Board||0.58yr||no data||no data|
Experienced Board: ORGS's board of directors are considered experienced (4.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 36.9%.
Orgenesis Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Orgenesis Inc.
- Ticker: ORGS
- Exchange: NasdaqCM
- Founded: 2008
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$110.251m
- Shares outstanding: 22.09m
- Website: https://www.orgenesis.com
Number of Employees
- Orgenesis Inc.
- 20271 Goldenrod Lane
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ORGS||NasdaqCM (Nasdaq Capital Market)||Yes||Common Shares||US||USD||Oct 2009|
|45O||BST (Boerse-Stuttgart)||Yes||Common Shares||DE||EUR||Oct 2009|
Orgenesis Inc. offers biotechnology solutions focusing on cell and gene therapies (CGTs). The company's Point of Care (POCare) platform includes three enabling components: a pipeline of licensed POCare The ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/26 05:31|
|End of Day Share Price||2020/10/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.